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Genstudie av medfødt og opptrent kondisjonsnivå 
Relasjoner til metabolsk syndrom 
 
Kondisjonsnivå har mye å si i en aktiv hverdag, men har også vist seg å kunne forutsi risikoen 
for å utvikle hjerte- og karsykdommer. Kondisjonsnivået sier faktisk mer om risikoen for 
hjerte- og karsykdom enn de kjente risikofaktorene slik som høyt kolesterol, fedme og 
røyking. Selv om hjerte- og karsykdommer er blitt kraftig redusert her i landet de siste tiårene, 
er det fortsatt den alvorligste dødsårsaken i Norge. Siden utholdenhetstrening øker 
kondisjonsnivået, minker samtidig sjansen for utvikle hjerte- og karsykdommer hos de som 
trener regelmessig. Dette er en kjent sak, men vi vet fremdeles lite om er hva som skjer med 
genene våre når vi trener. Hovedmålet for prosjektet var derfor å identifisere gener og 
cellulære prosesser som er assosiert med medfødt og opptrent kondisjonsnivå. Tanken bak 
dette er at de flere av de samme genene og cellulære prosessene sannsynligvis også er relatert 
til risiko for hjerte- og karsykdom.  
 
Vi sammenliknet genuttrykk i hjertet (studie I) og skjelettmuskulaturen (studie II) hos rotter 
med medfødt høyt- og lavt kondisjonsnivå, og studerte endringene ved trening hos begge 
disse gruppene. Det viste seg at de rottene med lavt kondisjonsnivå hadde en opphopning av 
risikofaktorer for hjerte- og karsykdom, som fedme og høyt blodtrykk, i tillegg til høyt nivå 
av både glukose og fett i blodet. Disse funnene tyder på at rottene med medfødt lav kondisjon 
har utviklet metabolsk syndrom (en diagnose for individer med opphopning av risikofaktorer 
for hjerte- og karsykdom). I hjertet fant vi store forskjeller i genuttrykk avhangig av om man 
var født med høyt- eller lavt kondisjonsnivå. Disse tydet på at energibruken var forskjellig 
avhengig av om de hadde høyt- eller lavt kondisjonsnivå. I tillegg hadde de med lavt 
kondisjonsnivå tegn på sykelig vekst av hjertet. Disse genetiske endringene kan settes i 
sammenheng med utvikling av hjerte- og karsykdom, og bør studeres videre for å avdekke 
potensielle angrepspunkter for forebygging og behandling. I skjelettmuskelen fant vi tegn på 
at lavt kondisjonsnivå kunne ha en sammenhang med en mutasjon som fører til dårlig 
energiproduksjon i cellene. Mennesker med denne mutasjonen og rottene med lavt 
kondisjonsnivå har flere likheter, som diabetes, og intoleranse for trening.     
 
Flere studier viser at intervall trening (4x4 prinsippet) er den mest effektive treningsmetoden 
for å øke kondisjonsnivået. Vi har derfor valg å bruke dette treningsregimet i alle tre studiene. 
Treningen ga størst genetisk forandring i skjelettmuskel hos rottene som var født med høyt 
kondisjonsnivå, hvor vi fant tegn på forbedret evne til å ta opp fett og omdanne til energi. 
Dette skyldes sannsynligvis at hjertet hos disse rottene har god kapasitet for blodforsyning, og 
at muskelen derfor kan respondere normalt på trening. I studie 3 undersøkte vi genetiske 
endringen i blod hos pasienter med metabolsk syndrom. Etter 16 uker med trening fant vi 
flere endringer i genuttrykk som kanskje kan forklare den forbedringen vi fant i karfunksjon. 
Slik informasjon kan være nyttig for å forstå mekanismene bak forbedret helse ved trening.         
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Definitions 
 
Artificial selection: In a genetically isolated population, random mating is prevented 
and mating is limited to those individuals who exhibit desired characteristics. 
 
Gene and protein nomenclature: Gene and protein names are abbreviated in different 
ways depending on species.  
 
Species Gene symbol Protein symbol
Homo sapiens SHH SHH 
Rattus norvegicus Shh SHH 
 
 
Gene expression: The process by which inheritable information from a gene, such as 
the deoxyribonucleic acid (DNA) sequence, is made into a functional gene product, 
such as acid ribonucleic (RNA) or protein. Several steps in the gene expression process 
may be modulated, including the transcription step and the post-translational 
modification of a protein. Gene regulation gives the cell control over structure and 
function, and is the basis for cellular differentiation, morphogenesis and the versatility 
and adaptability of any organism. Gene regulation may also serve as a substrate for 
evolutionary change, since control of the timing, location, and amount of gene 
expression can have a profound effect on the functions of the gene in the organism. 
 
Maximal oxygen uptake: The highest oxygen (O2) uptake that can be achieved by an 
individual during exercise with dynamic use of a large muscle mass; considered as the 
best indication of cardiorespiratory capacity. 
 
MELAS: A progressive neurodegenerative disorder. The features of the illness includes 
metabolic disorders caused by dysfunction of mitochondrial DNA, lactic acidosis, 
stroke-like episodes, seizures, diabetes mellitus, and exercise intolerance. 
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 Metabolic syndrome: To be diagnosed with the metabolic syndrome according to the 
definition from the World Health Organisation (1999), at least one of the three 
following diagnoses must be present: 
• type 2-diabetes 
• impaired glucose tolerance 
• impaired fasting glucose or insulin resistance 
in addition to at least two of the following diagnoses: 
• blood pressure: ≥ 140/90 mmHg  
• dyslipidaemia: triglycerides ≥ 1.695 mmol/L + circulating high-density 
lipoprotein (HDL) ≤ 0.9 mmol/L ♂ ≤ 1.0 mmol/L ♀ 
• central obesity: waist/hip ratio > 0.90 ♂  > 0.85 ♀, and/or Body Mass Index > 
30 kg/m2 
• microalbuminuria: urinary albumin excretion ≥ 20 mg/min or albumin/creatinine 
≥ 30 mg/g  
 
MIAME: Minimum Information About a Microarray Experiment is a standard for 
reporting microarray experiments. It is intended to specify all the information necessary 
to interpret the results, and to potentially reproduce the experiment.  
 
Microarray: A high-throughput technology used in molecular biology and in medical 
research. The microarray consists of thousands of microscopic spots of DNA 
oligonucleotides, that each contains picomoles of a specific DNA sequence or a short 
section of a gene (probe). Cyclic DNA (cDNA) or cyclic RNA (cRNA) from the sample 
being studied hybridizes to these probes under high-stringency conditions. Probe-target 
hybridization is usually detected and quantified by fluorescence to determine relative 
abundance of nucleic acid sequences in the sample. In standard microarrays, the probes 
are bound to a solid surface by covalent attachment to a chemical matrix.  
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Background 
The Western society epidemic of lifestyle-related diseases is an impending threat to 
public health, and calls for effective prevention and treatment strategies1. Exercise 
training may represent such a strategy, as there is a close line between an individual’s 
fitness level and long-term prognosis2. Identifying the cellular and molecular 
mechanisms associated with aerobic fitness is important, because it may help us develop 
new and better methods to prevent and treat cardiovascular disease (CVD). From the 
HERITAGE Family Study we are starting to get a glance of which genes that contribute 
to the adaptations to exercise, but currently little information is available on the 
combination of individual lifestyle factors, environmental influences and genetic factors 
in determining an individual’s level of physical fitness3, 4. Recently, gene expression 
profiling using microarrays have revealed unexplored fields of biomarker discovery and 
gene expression profiling of disease. Microarray technology is constantly improving, 
and might represent an important tool for identifying the genes associated with aerobic 
fitness level and CVD.  
 
 
The metabolic syndrome 
The metabolic syndrome is defined as a cluster of conditions that may predispose for 
CVD (see Definitions). Although each of these factors is an independent predictor of 
cardiovascular mortality, they become more potent than the sum of each single 
parameter when occurring together. In recent years, there has been an expansion in the 
knowledge about how inactivity interacts with genes and forms a basis for development 
of chronic disease1. Some argue that the modern human is still genetically adapted to 
the hunter-gatherer lifestyle because the human genome has changed little during the 
past 10,000 years. Accordingly, today’s genotypes could have evolved through natural 
selection in an environment were physical activity were obligatory for survival5. Booth 
et al. speculated whether humans carry a set of disease susceptibility genes that 
produces some relative risk which, in combination with physical inactivity, could lead 
to chronic disease6. Following this argument, the human body is thus not ideally suited 
for a modern Western lifestyle where we maintain only 38% of the daily energy 
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expenditure as compared to our ancestors1. Today, the metabolic syndrome is one of the 
most challenging threats to human health in the Western civilization, and is now present 
in about 25 % of the US adult population7, 8. 
 
The pathophysiology of the syndrome is complex and has only partially been 
elucidated. The most important factors for developing the metabolic syndrome seem to 
be aging, genetics and lifestyle (physical activity and diet)7, 9. There has been debate 
regarding whether obesity or insulin resistance is the cause of the metabolic syndrome 
or whether they are consequences of a more far-reaching metabolic disorder. Given the 
growing number of persons suffering from the metabolic syndrome, more knowledge on 
the genetic susceptibilities is urgently needed. 
 
There are several more or less efficient treatment strategies for the metabolic syndrome 
today, as lipid, cholesterol, and blood pressure lowering drugs10. However, with the 
syndrome reaching a pandemic, these treatment strategies do not seem to be very 
successful. A major goal is to treat both the underlying cause of the syndrome, and the 
CVD risk factors if they persist. Accumulating evidence indicate that regular physical 
activity has profound beneficial effects on both prevention and treatment of the 
metabolic syndrome, although the mechanisms are still unclear11-16. Moreover, several 
studies indicate that there is an inverse relationship between the incidence of the 
metabolic syndrome and aerobic fitness17-21. Interestingly, rats selected over generations 
for low aerobic fitness (Low Capacity Runners; LCR rats) that were exposed to the 
same environmental factors as rats selected for high aerobic fitness (High Capacity 
Runners; HCR rats) developed characteristics that fit into the definition of the metabolic 
syndrome22. This indicates a very strong genetic factor determining the predisposition 
for the syndrome. 
 
Maximal oxygen uptake 
Maximal O2 uptake (VO2max) is dependent on the lung ventilatory capacity, the hearts 
pumping ability, the function of the endothelium, the O2-carrying capacity of blood (i.e. 
hemoglobin) and the capacity of utilizing O2 in mitochondrial respiration. The higher 
 13
VO2max, the more O2 has been transported to and used by exercising muscles, which 
increases the level of intensity at which the individual can exercise.  
 
VO2max is determined both by genetic and environmental factors23. The genetic factors 
contribute to the untrained fitness level, but also the potential of training-induced 
improvements24, 25. Since low VO2max is a strong and independent predictor of the 
metabolic syndrome and cardiovascular mortality, the ability to deliver and utilize O2 
during exercise seems to represent a point of divergence for cardiovascular health2, 17-21, 
26-28. In patients with insulin-resistance, the low VO2max is associated with impaired 
mitochondrial function that has largely been attributable to impaired skeletal muscle 
glucose metabolism29, 30. These observations are consistent with impaired regulation of 
mitochondrial function as an important mechanism for low VO2max and cardiovascular 
risk factors linked to the metabolic syndrome. Also in rats born with a low VO2max 
(LCR rats), impaired mitochondrial function is suggested to be a leading cause of 
impaired O2 uptake22.  
 
Endurance training is a physiologically attractive treatment strategy for the metabolic 
syndrome. Endurance training improves blood pressure, endothelial function, whole-
body glucose disposal, insulin sensitivity, caloric expenditure, neurohormonal factors, 
body composition, and lipid metabolism11, 20, 31. Due to the inverse relationship between 
VO2max and the metabolic syndrome, exercise that increases VO2max the most, is 
potentially the most effective treatment strategy. Several studies now agree that high-
intensity aerobic interval training is superior to moderate training in improving VO2max 
in healthy individuals, healthy rats, patients with coronary artery disease, and patients 
with post-infarction heart failure (HF)32-36. 
 
Recently, the HERITAGE Family Study investigated the role of genetic contribution to 
the individual response to endurance training24. A significant genetic component in the 
trainability of VO2max was reported, which means that the degree to which VO2max can 
be improved by exercise varies widely in the human population. Some families were 
characterized by a high trainability pattern, whereas others were characterized by low 
responsiveness with little or no benefits of training. The heritability was determined to 
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be 47 %, and a significant maternal effect was observed. This raised the possibility that 
mitochondrial DNA is involved in determining the individual training response. Since 
inborn and acquired VO2max has a strong genetic component, it should be feasible to 
identify the genes or mutations responsible for determining inborn VO2max and the 
response to exercise training.  
 
Exercise-induced improvements in VO2max depend mainly upon adaptations in the 
skeletal muscle, blood vessels and in the heart, as lung function is hard to improve by 
means of exercise. 
 
The heart 
The metabolic syndrome has damaging effects on the heart, and triggers several 
maladaptive responses in the myocardium. Due to insulin resistance, the metabolic 
syndrome heart is susceptible to energy deprivation, cardiomyopathy, diastolic and 
systolic dysfunction, impaired contractility, pathological left ventricle (LV) 
hypertrophy, and fibrosis37, 38. However, most of these conditions can be reversed by 
performing regular endurance training. After long-term endurance training, growth 
mechanisms are activated that causes an increase in LV chamber size, wall thickness 
and total mass39. Consequently, stroke volume (SV) and O2 delivered to working 
muscles increases. In addition, sympathetic activity and myocardial O2 demand 
decreases, whereas vagal tone is enhanced40, 41. For metabolic syndrome patients, 
exercise-induced improvements of insulin sensitivity and are therefore particularly 
important, to progressively reduces the risk of cardiovascular events.  
 
Cardiac hypertrophy 
Cardiac hypertrophy is an adaptive response of the heart to preserve LV function in 
physiological or pathological states42-44. 
 
Physiological cardiac hypertrophy, induced by long-term endurance training, normal 
body growth, and pregnancy, triggers functional and morphological changes in the 
heart, to meet increased demands while maintaining normal LV function39. 
 15
Physiological LV hypertrophy includes different hypertrophy patterns that are induced 
by different forms of exercise training. Strength training increases peripheral resistance, 
or afterload, thereby stimulating concentric hypertrophy. Long-term endurance training 
increases venous return and blood volume, and hence preload, and is therefore a 
stimulus for eccentric LV hypertrophy45, 46. The cardiac physiological hypertrophy seen 
with normal body growth (i.e. more muscle mass to serve) and endurance training 
increases contractility, SV, and cardiac performance, allowing the individual to exercise 
at higher workloads47.  
 
The heart adapts to excess hemodynamic load by compensatory hypertrophy, which, 
under conditions of persistent strain, over time evolves into cardiac dysfunction. Like 
the physiological counterpart, pathological LV hypertrophy also includes different 
hypertrophy patterns. Pressure-overloaded (concentric) hypertrophy results in a 
substantially increased wall thickness to chamber radius ratio. In contrast, volume-
overloaded (eccentric) hypertrophy results in a normal wall thickness to chamber radius 
ratio48. Moreover, the course of HF is characterized by transitions between a series of 
interconnected phenotypes, resulting in a dilated heart with a thin wall and a large heart 
chamber. In addition, after myocardial infarction, loss of viable myocardium results in 
compensatory changes in the remaining viable muscle, which is highly heterogeneous. 
Pathological cardiac hypertrophy is deleterious because it increases the O2 demand of 
the heart and decreases mechanical efficiency. Sustained pathological hypertrophy often 
leads to systolic and diastolic dysfunction, and is regarded as an independent risk factor 
of cardiovascular morbidity and mortality49. Metabolic syndrome patients may suffer 
from both hypertension-dependent and hypertension-independent LV pathological 
hypertrophy50, 51. In normotensive patients, both type 2-diabetes and 
hypercholesterolemia have been found to independently cause maladaptive cardiac 
growth51.  
 
Physiological and pathological cardiac growth, is suggested to be triggered by an 
interaction of mechanical forces and neurohormonal factors52. Most of the extracellular 
stimuli (ions, hormones, cell mediators, and mechanical signals) are integrated and 
transmitted by various intracellular signalling pathways to the cell nucleus where gene-
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expression is altered53, 54. Pathological remodelling is mainly triggered by 
neurohormonal factors (angiotensin-II, endothelin-1, and catecholamines) through G-
protein-coupled receptor signalling pathways54. Downstream, the pathway involves 
phosphatidylinositol bisphosphate, diacylglycerol, and inositol triphosphate (IP3). IP3 
releases calcium (Ca2+) from intracellular stores, which may activate e.g. the calcineurin 
pathway and trigger transcription of hypertrophic genes55. In addition, a complex web 
of signalling pathways has been implicated in cardiac hypertrophy. In contrast, 
physiological hypertrophy appears to be triggered by growth hormone (GH) and insulin-
like growth factor (IGF) and regulated e.g. through the phosphoinositide-3 kinase-Akt 
pathway56. Changes in gene expression induced by this cascade, allow the heart to 
produce normal active tension at a lower cost in terms of energy expenditure.  
 
Based on the close relationship between cardiac phenotype and VO2max, differences in 
inborn VO2max might also be related to different cardiac growth patterns57-59. Whether 
the inborn level of VO2max is associated with a particular growth pattern is currently 
unknown.  
 
Cardiac function, contractility and Ca2+ handling 
In metabolic syndrome patients, the frequency and/or the severity of systolic and 
diastolic dysfunction seem to increase with the number of components of the metabolic 
syndrome60. Myocardial contractile dysfunction is characterized by altered Ca2+ 
handling and excitation contraction coupling that leads to impaired cardiomyocyte 
fractional shortening and relaxation. 
 
Cardiomyocyte fractional shortening is initially activated by depolarisation of the 
sarcolemma membrane. Depolarisation of the membrane opens voltage gated Ca2+ 
channels (L-type Ca2+ channels), which due to the electrochemical gradient over the 
sarcolemma, leads to an influx of Ca2+ to the cytosol. This small increase in Ca2+ opens 
the Ca2+ sensitive ryanodine receptors located at the sarcoplasmic reticulum (SR), 
leading to a large Ca2+ release from the SR. The free intracellular Ca2+ binds to troponin 
C and initiates the adenosine triphosphate (ATP) dependent movements of actin and 
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myosin. For diastolic relaxation to occur, Ca2+ must be removed from the cytosol. The 
removal of intracellular Ca2+ occurs via transport over the sarcolemmal membrane or 
reuptake into the SR. In rats, 92 % of the Ca2+ re-enters the SR via the SR Ca2+ -ATPase 
2a (SERCA2a). The remaining 8 % is extruded over the sarcolemma via the Na+/Ca2+ 
exchanger, and the sarcolemmal Ca2+- ATPase, or enters the mitochondria via the 
mitochondrial uniporter61. 
 
Disruption of intracellular Ca2+ handling is one of the key factors of contractile 
dysfunction in heart disease, and has been documented in cardiomyocytes from rats 
with features of the metabolic syndrome (LCR rats), and in rats and patients with HF22, 
62-65. This may partly be explain by reduced SERCA2a levels, combined with decreased 
phosphorylation of phopholamban depressing the re-uptake of Ca2+ to the SR66, 67. As a 
compensation for lower SERCA2a content and activity the Na+/Ca2+ exchanger is 
relatively given more significance as its expression is increased68. However, this 
compensation may lead to lower SR Ca2+ content as the Na+/Ca2+ exchanger removes 
Ca2+ over sarcolemma and out of the cell.  
 
Alterations in the abundance and/or activity of L-type Ca2+ channels and the ryanodine 
receptors have also been associated with abnormal Ca2+ regulation69, 70. In concert, this 
may together with lower SR Ca2+ lead to a dys-synchronised and diminished Ca2+ 
release from the SR71. Increased sensitivity of the ryanodine receptors to Ca2+, increases 
the frequency of spontaneously, uncontrolled Ca2+ release from the SR. This feature 
may reduce the SR Ca2+ storage, decrease Ca2+ amplitude, reduce cardiomyocyte 
contraction, and lead to depressed systolic function72. Moreover, altered Ca2+ 
myofilamament sensitivity is also a common feature in cardiac dysfunction73, 74.  
 
It is previously shown that endurance training improves myofilament Ca2+ sensitivity, 
cardiac contractile performance, and Ca2+ handling in healthy rats, rats with features of 
the metabolic syndrome (LCR rats) and in rats with HF22, 36, 59, 74. However, further 
investigations are needed to fully understand the mechanism of improved Ca2+ handling 
with exercise, as well as the impaired Ca2+ handling in heart disease.  
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Cardiac metabolism 
Cardiac muscle fibres have the highest mitochondrial density of all tissues, and rely 
almost exclusively on energy released from aerobic reactions. In healthy hearts, the 
preferred substrate for mitochondrial respiration is free fatty acid (FFA), accounting for 
60–80% of the total energy consumption. However, after a meal and during intense 
exercise, the preferred energy substrates are glucose and lactate, respectively. In 
essence, the heart metabolizes the substrates offered by the circulation at different 
circumstances.  
 
Pathological conditions of the heart often involve changes in cardiac energy metabolism 
like increase in glucose oxidation, and downregulation of enzymes involved in fatty 
acid oxidation (FAO)75, 76. Initially, enhanced glucose oxidation improves cardiac 
efficiency, since the amount of ATP produced per O2 consumed is higher. However, as 
the pathological condition progresses towards an uncompensated state, the capacity of 
utilizing glucose decreases, and hence the efficiency of the heart77. Increased glucose 
metabolism and impaired cardiac O2-supply leads to increased anaerobic metabolism at 
high work loads75. Anaerobic metabolism has lactic acid as a major metabolite, which 
consequently results in cardiomyocyte acidosis, which directly influences the 
cardiomyocyte contractile properties78. 
 
In metabolic syndrome patients, the plasma levels of glucose and FFAs are often 
elevated. The latter may result in increased intracellular levels of FFAs and their 
derivatives, which potentially inhibit insulin mediated glucose transport in 
cardiomyocytes. However, despite less insulin-mediated glucose entrance, glucose 
uptake in diabetic hearts is often normal because of the hyperglycemia76. Therefore, also 
glycolytic intermediates may accumulate in the cardiomyocytes. 
 
Regular endurance training may improve detrimental cardiac energy metabolism in 
diseased hearts79. Regular endurance training will augment myocardial blood flow 
because of myocardial neovascularisation, and provide a more effective control of 
vascular tone and blood distribution80-82. However, direct evidences for beneficial 
effects of endurance training on cardiac energy metabolism are sparse. Hence, more 
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studies are needed to elucidate the changes in cardiac energy metabolism by exercise 
and the genetic basis for this.  
 
Skeletal muscle 
Skeletal muscle tissue constitutes about half of the body mass and play a fundamental 
role in whole body metabolism. In the last decade, our modern lifestyle with physical 
inactivity has impaired skeletal muscle contractile and metabolic functions, contributing 
to the epidemic emergence of the metabolic syndrome.  
 
Although genes, sex, body size, and age are the primary determinants of muscle mass, 
skeletal muscles have a tremendous capacity to adapt structurally and functionally to 
exercise by altering gene expression that affects growth and metabolism83. 
Transcriptional alterations in skeletal muscle regulatory genes occur within hours after 
an exercise bout, e.g. enzymes regulating FAO and oxidative phosphorylation 
capacity83-85. In contrast, transcriptional alterations of structural genes e.g. components 
of mitochondria and capillaries, occurs a few weeks into the exercise program86-88. 
Increased metabolic activity is necessary for structural adaptations and increase 
workload in muscle with exercise training. Therefore, exercise training is accompanied 
by increased number and volume of mitochondria, increased mitochondrial enzyme 
activity, and increased production of nitric oxide (NO) that improves O2 and nutrient 
availability by increasing flow and perfusion89. A genetically determined limitation in 
skeletal muscle O2 delivery and utilisation has previously been reported in the LCR rat 
model90. The activity of skeletal muscle oxidative enzymes, e.g. citrate synthase, was 
significantly decreased as compared with rats with no limitations in O2 delivery and 
utilisation (HCR rat model)90. If skeletal muscle is subjected to O2 deficiency during 
work, ATP production may be insufficient and structural adaptations may not occur. 
Studies of exercise training at hypoxia and normoxia show evident differences in 
skeletal muscle gene expression depending on the availability of O291, 92. In the case of a 
normal, healthy muscle, decreased O2 delivery during endurance training often involves 
adaptations that favour O2 transport and utilization91. 
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Skeletal muscles are targets in prevention and treatment of the metabolic syndrome, due 
to their important role in consuming and removing energy substrates (lipids and 
glucose) from the circulation. Under normal circumstances, plasma FFAs is the 
predominant fuel for skeletal muscle, although supplemented by circulating very low-
density lipoprotein (VLDL), triglycerides, lactate and glucose93. Under insulin-
stimulated conditions (i.e. after a meal), skeletal muscle accounts for as much as 80 % 
of whole-body glucose elimination, and is therefore the primary tissue responsible for 
peripheral disposal of glucose94.  
 
Evidence indicates profound beneficial effects of exercise training in metabolic 
syndrome patients due to cellular adaptations in skeletal muscles. However, the 
mechanisms are far from understood and need further evaluation. The improved whole 
body metabolism (Figure 1) accomplished by exercise training is likely to be a central 
mechanism behind improved health by exercise. During exercise, skeletal muscle lipid- 
and glucose metabolism increases, and contributes significantly to the peripheral 
disposal of glucose. Despite increased fatty acid (FA) metabolism, the level of 
circulating FAs remains quite stable due to a simultaneous increased hydrolysis of 
intramyocellular triglycerides releasing FFA to the circulation. Long-term endurance 
training involves alterations in metabolic substrate preference in muscle with a greater 
reliance on lipid, rather than carbohydrates. This has beneficial effects on the muscles 
due to reduced formation of lactic acid, glycogen sparing, reduces high-energy 
phosphate utilization, and reduces muscle fatigue. Although much is known regarding 
exercise-induced changes in metabolism, many of the detailed molecular mechanisms 
and genes involved remains to be identified. 
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Figure 1. Summary of metabolism. CO2: Carbon dioxide, NH3: Ammonia, H+: Hydrogen ion, e-: 
Electron, ADP: Adenosine diphosphate, ATP: Adenosine triphosphate, O2: Oxygen, H2O: Water.  
 
 
Circulating factors and the endothelium 
Blood samples can provide useful indication of the CVD risk and contribute to a clinical 
diagnosis of the metabolic syndrome. Blood from metabolic syndrome patients often 
contains low levels of HDL, as well as elevated levels of prothrombotic- and 
proinflammatory factors, triglycerides, glucose and insulin. Although increased levels 
of prothrombotic- and proinflammatory factors are not included in the diagnostic 
criteria, metabolic syndrome patients often suffer from a chronic low-level 
inflammation process, dys-regulated coagulation system and impaired platelet 
function13. Therapies that improve insulin sensitivity, hyperinsulinemia, and metabolic 
abnormalities has been shown to decrease the prothrombotic state95.  
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Several of the factors that constitute the metabolic syndrome, has destructive effects on 
the innermost surface of blood vessels, the endothelium. The endothelium regulates 
vascular tone, and inhibits platelet aggregation and atherosclerosis. The most important 
endothelium-derived factor is NO, based to the vide variety of paracrine actions, 
ranging from being the most potent endogenous vasodilator, to counteracting 
atherosclerosis96. NO is produced by endothelial NO synthase, and uses L-arginine as 
substrate. Diminished bioavailability of NO, through decreased production or increased 
degradation, may lead to endothelial dysfunction. In diabetic animals, increase NO 
degradation by free radicals has devastating effects on cardiovascular system by 
inactivating NO and forming the cardio-toxic peroxynitrite97. Loss of proper endothelial 
function is an early pathogenic event of the metabolic syndrome that often appears 
decades before the onset of vascular disease98. Endothelial dysfunction is often seen in 
patient with hypertension, hypercholesterolemia, type 2-diabetes, and in smokers99, 100. 
The degree of endothelial dysfunction is proportional to the severity of insulin 
resistance; however, the cause-and-effect relationship is unclear and should be further 
studied101.     
 
Several studies suggest that improved cardiovascular health by regular physical activity 
is mediated, at least partly, through re-establishment of the haemostatic balance and 
endothelial function102, 103. Since substances involved in the metabolic syndrome (low-
density lipoprotein (LDL), HDL, glucose, insulin, triglycerides) are constantly 
interacting with blood cells, blood cells might also be involved in the pathogenesis of 
the metabolic syndrome and the endothelial dysfunction. Studies are needed to elucidate 
whether blood cells alter their gene expression as a concequence of exercise training in 
metabolic syndrome patients, and whether altered properties of blood cells might be 
involved in improvements of endothelial function and the metabolic syndrome.    
 
Fighting the metabolic syndrome 
Non-pharmacological lifestyle changes, as exercise and dietary modifications, constitute 
the most important treatment strategies for the metabolic syndrome. The most feasible 
symptoms to treat by changes of lifestyle are endothelial dysfunction and insulin 
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resistance. Although we know how to treat the syndrome effectively with exercise and 
dietary modifications, the prevalence of the syndrome increases yearly, possibly 
because of ignorance, and lack of commitment to a healthy lifestyle. Therefore, new 
treatment strategies are urgently needed to cope with this expanding problem. To 
achieve this goal, it is essential to define a set of candidate genes involved in the 
development and/or progression of this syndrome. Since exercise is an efficient 
treatment strategy of the metabolic syndrome, genes altered by exercise also represent 
possible drug targets of the treatment of the metabolic syndrome.  
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Aims 
Since VO2max is a strong predictor of cardiovascular mortality, genes related to low 
VO2max may also be related to the metabolic syndrome and CVD. As skeletal muscle, 
blood and the heart are involved in the pathology of the metabolic syndrome, we 
hypothesed that genes predisposing for CVD are expressed in these organ systems. 
Therefore, the main purpose was to uncover gene expression profiles associated with 
different levels of both inborn and acquired VO2max.  
 
The specific aims were to: 
A. Determine if rats born with a great difference in running capacity and VO2max 
(HCR/LCR model) have different LV gene expression and different soleus 
muscle gene expression. 
 
B. Study whether the gene expression profile of LCR may explain the low VO2max 
and increased cardiovascular risk. 
 
C. Determine if rats born with different VO2max respond differently to the same 
exercise protocol in terms of altered gene expression.  
 
D. Determine whether transcriptional changes occur in blood cells of metabolic 
syndrome patients in response to 16 weeks of high intensity interval training.  
 
E. Study whether the exercise-induced changes in gene expression (D) may explain 
the improved health status achieved by the metabolic syndrome patients after the 
exercise intervention. 
 
 
 
 
 
 25
Methodological considerations 
Animal model 
To study intrinsic VO2max in a situation were environmental factors are minimised, we 
used an artificially selected rat model of high capacity runners (HCR) and low capacity 
runners (LCR) with 30% difference in inborn VO2max and 432% difference in inborn 
running capacity (Figure 2)22, 90, 104-117. In the HCR/LCR-model, genes responsible for 
aerobic fitness are concentrated, while environmental components are minimized by 
maintaining a standardized environment. This makes the HCR/LCR-model of 
substantial value for determining the genes causative of variation in VO2max. Moreover, 
as almost all human genes known to be associated with disease have orthologues in the 
rat genome, the rat is a highly applicable model for gene expression analyses in 
translational medical research118.   
 
 
Figure 2. Response to selection for aerobic treadmill-running capacity across 16 generations. The HCR 
group was estimated to increase by 29.7 meters per generation, whereas the LCR group was estimated to 
decrease 5.2 meters per generation. HCR: High capacity runners, LCR: Low capacity runners. 
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Interestingly, at generation 16 (which was studied in this thesis), LCR have 
accumulated risk factors of CVD, such as hypertension, endothelial dysfunction, insulin 
resistance, impaired glucose tolerance, visceral adiposity, hyperglycemia, 
hypertriglyceridemia, and elevated plasma FFAs; commonly diagnosed as the metabolic 
syndrome22, 107. In addition, LCR have decreased SV, as well as impaired O2 supply, 
extraction ratio and tissue diffusion capacity in skeletal muscle as compared to HCR90, 
106, 113. LCR also have impaired systolic and diastolic cardiac function107. The impaired 
systolic function was manifested by impaired cardiomyocyte contractility, increase time 
to peak contraction, low levels of systolic Ca2+ and increased time to peak Ca2+ 
concentrations107. The diastolic dysfunction involved slow cardiomyocyte relaxation, 
less efficient Ca2+ removal, as well as high levels of diastolic free Ca2+.  
 
Recently, impaired tissue oxygenation due to reduced O2 supply, extraction, and tissue 
diffusion capacity were reported in LCR106, 113. This was not surprising, since running 
capacity is related to the ability to deliver and utilize O2119. Since the O2 uptake of LCR 
is limited by supply, extraction ratio, and diffusion capacity, several systems/organs are 
likely to be involved in the low VO2max phenotype.   
 
Metabolic syndrome patients 
In Paper III, we analysed blood samples collected from 7 males and 4 females 
diagnosed with the metabolic syndrome (according to the World Health Organisation 
criteria), before and after a 16-week high-intensity exercise program. During the 
exercise period, these patients had significantly improved VO2max, endothelial function 
(in terms of flow-mediated dilatation in the brachial artery), insulin signalling in fat and 
skeletal muscle and blood pressure, hence reducing their risk of later developing 
CVD11. In addition, 47% of the patients were no longer classified as having the 
metabolic syndrome. This high success rate makes this approach an effective treatment 
strategy for the metabolic syndrome, and a useful model to study the relationship 
between improvements of the features of the metabolic syndrome and changes in gene 
expression. Given the growing number of persons suffering from the metabolic 
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syndrome, more knowledge on how genetic susceptibilities interact with exercise is 
urgently needed. 
 
Interval training program 
Rats performing high-intensity interval training display most of the cardiorespiratory 
changes observed in humans, as increased VO2max, physiological cardiac hypertrophy, 
improved endothelial function and reduced resting heart rate36, 59, 120. Most of the 
changes occur within the first four weeks of endurance training, and VO2max reaches a 
plateau after six to eight weeks36, 120. High-intensity aerobic interval training by 
treadmill running is a very efficient method of improving VO2max32-35. Interval training 
is designed to challenge the pumping capacity of the heart to a greater extent than 
moderate continuous exercise. Several studies now agree that high-intensity aerobic 
interval training is superior to moderate training in improving VO2max, in healthy 
individuals, healthy rats, patients with coronary artery disease, and patients with post-
infarction HF32-36. Therefore, both laboratory animals and metabolic syndrome patients 
in this thesis were recruited to aerobic interval training at high-intensity, to most 
efficiently increase VO2max and combat metabolic abnormalities. 
 
Both rats and patients performed uphill running/walking on a treadmill, although the 
rats at a higher inclination than the patients. The rats ran for 1.5 hours five times a week, 
alternating between eight minutes at an exercise intensity corresponding to 85-90% of 
VO2max, and two minutes active recovery at 50-60%. This model was established by 
Wisløff et al. and ensures a robust training response that involves increased VO2max, 
physiological cardiac hypertrophy, improved contractile function, and reduced resting 
heart rate35, 59, 120. In contrast to the rats, patients performed 40 minutes of exercise three 
times a week, alternating between four minutes at an exercise intensity corresponding to 
~90% of maximal heart frequency, and three minutes of active recovery at 70%. The 
exercise program for rats and patients lasted for 8 and 16 weeks, respectively. To adjust 
running speed in order to maintain the intended intensity for the rats throughout the 
experimental period, VO2max was measured at the start of every training week. To 
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maintain the intended intensity for the patients speed or inclination was increased 
during the exercise period.  
 
Tissue collection 
The LV and soleus muscles were collected when the rats were approximately 7 months 
old, and 48 hours after their last exercise session. This was done to avoid any acute 
effects of exercise. Since expression of regulatory and metabolic genes tends to occur 
within few hours after exercise training, and often returns to baseline within 24 hours, 
sample collection after eight weeks of endurance training, and 48 hours after the last 
exercise selection means that we probably lose sight of several of the differentially 
expressed genes87, 121. However, this was intended, since we were interested in the long-
term adaptations to exercise. Since we were studying effects of aerobic exercise 
training, we chose to analyse the soleus muscle rather than other leg muscles, because of 
its high concentration of aerobic slow fibres.  
 
Blood samples from metabolic syndrome patients were collected before and after the 
training intervention, and 72 hours after the last exercise session to avoid acute effects 
like changes in number and phenotype of circulating leucocytes122. To minimise 
potential environmental factors, sample collection was performed at the same time of 
day after 12 hours of fasting. Blood cells possibly contributing to the gene expression 
profile of the metabolic syndrome patients are illustrated in Figure 3. 
 
To avoid potential RNA degradation, samples from LV, soleus muscle and blood were 
treated with caution. The samples from soleus muscle and LV were snap-frozen in 
liquid nitrogen, whereas the blood samples were collected on specialized PAXgene 
tubes to ensure RNA integrity. Samples for verification of microarray data were 
collected at the same time as the samples for microarray analysis. This included plasma 
from the patients, and additional tissue from the LV and soleus from the rats. All 
samples were stored at -80 o C until assayed. 
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 Figure 3. Blood cells developing from the hemocytoblasts, which contain DNA and may contribute to the 
gene expression profile of metabolic syndrome patients. 
 
Cardiomyocyte measurements 
Cardiomyocytes were isolated from the LV in a standard Langendorff retrograde 
perfusion system to study their size, contractility, and Ca2+ handling (Paper I). The 
protocol has previously been described in detail by Wisløff et al120. From healthy LV, 
this protocol recovers about 10 % of the total number of cardiomyocytes, and about 75 
% are rod-shaped. Only viable, rod-shaped cells without obvious damage were selected 
for measurements. The advantages of using isolated cardiomyocytes as compared to the 
whole heart is that the cells are fully differentiated and morphologically similar to cells 
in the intact heart. Using isolated cells also allows for several parallel measurements 
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from the same animal, which is more effective and reduce the number of animals 
needed to be sacrificed. There are also some disadvantages with using isolated cells 
instead of the whole heart. The myocytes are separated from contact with other cells and 
are quiescent due to separation from pacemaker tissue. The myocytes could also have 
been modified during the cell isolation procedure, which may affect the reliability. 
However, to reduce this problem, myocytes from both untrained and trained rats were 
isolated on the same day.  
 
RNA isolation 
Messenger RNA (mRNA) is a copy of DNA and a recipe used to make different 
proteins. At a given time point, the mRNA level encoding different proteins reflects the 
cellular responses to different stimuli. In this thesis, RNA was isolated from LV (Paper 
I), soleus muscle (Paper II) and from whole blood (Paper III). Tissue-specific protocols 
for RNA isolation and RNA clean up were used for the different tissue types, according 
to the nature of the tissue, as viscosity and fibrousity. To ensure high mRNA quality, 
integrity, purity and quantity all samples were run on Bioanalyzer and Nanodrop. The 
Bioanalyzer system is a fully automated gel electrophoresis, analyzing the separation of 
bands in the sample to assess RNA quality. The Nanodrop instrument applies ultraviolet 
spectrophotometry at 260/280 nm to assess the concentration and quality of total RNA 
in the sample. Only samples with a 260/280 ratio between 1.8-2.2 and no signs of 
degradation were used for analysis. cDNA was later synthesized from RNA samples 
that fulfilled the quality criteria. cDNA was further processed to fragmented biotin-
labelled cRNA and hybridized to microarrays.  
 
Microarray gene expression analysis 
The sequencing of the entire human- and rat genome has opened a new era in 
biomedical research118, 123, 124. Improvements in microarray technology have had a 
significant impact on large-scale studies of gene expression, and today over 30.000 
transcripts can be measured on one single chip. The challenge is now to identify the 
biological functions of each gene, the diseases in which they are involved, and possible 
therapeutic targets of disease. A microarray experiment uses representative probes 
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corresponding to known genes, to which tissue mRNA is hybridized and quantified 
based on hybridization intensity. The experimental rationale is usually straightforward: 
hybridization data from two or more groups of samples are compared to seek evidence 
of differentially expressed genes. Despite the great promises of microarrays in health 
care, and their successes in both medical and biological research, the technology is still 
far away from daily use in the clinic. The reason for this is e.g. the costs of the 
microarrays and the costs to obtain a clean RNA sample, problems in getting tissue with 
satisfactory quality and quantity from hospitals after surgery, and the high variability in 
repeated studies. In the near future, ultrahigh-throughput sequencing technology will 
change the way gene expression is studied. Rather than relying on hybridization 
intensity from microarrays, the number of times transcripts are called in sequencing 
gives direct quantification of expression levels. For the time being, this method is 
expensive and time-consuming; therefore, microarray analysis is likely to remain the 
gold standard of whole-genome gene expression studies for some years to come. 
 
There exits several systems of microarray analysis, and in this thesis we have used the 
Affymetrix RAE 2.0 microarray chips (Paper I and II), and the Applied Biosystems 
Human Genome Survey Microarray v.2.0 chips (Paper III). These are both 1-channel 
systems with whole-genome coverage. When comparing the ten most common 
microarray platforms, the Applied Biosystems platform was ranked as number one, and 
the Affymetrix was ranked as number two when the microarray results were compared 
to single mRNA measurements for 160 chosen genes125.   
 
Affymetrix 
The Affymetrix chips consist of 31,042 probe sets that cover the entire rat genome. 
Each of the probe sets are represented by 11-20 probe pairs consisting of a perfect 
match and a mismatch probe. The expression value of each probeset is computed from 
background-corrected, quantile normalized and log-transformed perfect match values 
for each probe pair by use of the “robust multi-array analysis”126. To tests for 
significant differential expression between groups, a moderated T-tests is applied127. 
Due to the magnitude of probe sets being compared, we account for multiple testing by 
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the Benjamini-Hochberg step-up procedure which creates adjusted P-values128. When 
selecting genes with a P-value below 0.05, the expected proportion of genes falsely 
classified as differential expressed should be below 5%. No threshold for fold-change 
was used, based on our assumptions that a gene 25% upregulated, might be just as 
important as a gene found 100% upregulated. Differentially expressed genes were 
classified to gene networks, biological processes, molecular functions and cellular 
locations with the Ingenuity Pathway Analysis Application Tool and the eGOn web 
tool129. This approach provides a general impression of which processes separate the 
cases from the controls, which usually yields more information than studying single 
genes.  
 
Applied Biosystems 
The Applied Biosystem Human Genome Survey microarray v.2.0 contains 32,878 
probes for the interrogation of 29,098 genes. The expression values are computed from 
filtered, quantile normalized and log-transformed signal intensities. Weak spots and 
outliers were filtered out, and missing values were replaced by imputation using 
Adaptive LSimpute130. Probes were collapsed to genes, using Primary Gene ID from the 
Applied Biosystems Human Annotation File. All genes were ranked from the most to 
the least significant, using the paired “significance analysis of microarrays” statistical 
test131. Instead of looking for differential expression of individual genes, which has been 
the traditional way of doing it, we focused on changes in biological processes and 
molecular function. We therefore used the entire ranked list in the gene set enrichment 
analysis (GSEA)132 rather than selecting for instance the top 200 genes or genes with a 
P-value below a certain cut-off. This is preferred because it is difficult to decide where 
to set the cut-off. If the genes only change moderately it may be difficult to find 
significant changes by looking at each gene separately. If, on the other hand, many 
genes belonging to the same gene set are changed moderately this could be an 
interesting finding, and the defined relationship between these genes gives more 
statistical power to detect such small changes compared to single gene statistics. GSEA 
works by starting to look at the gene ranked on top of the gene list. If this gene is a 
member of a certain gene set, a positive score is added to an enrichment score (ES), 
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otherwise a negative score is added. Then the next gene on the gene list is evaluated and 
the ES is updated. This process is repeated for every gene in the entire gene list. The 
maximum value obtained during this “walk” is used as ES for the gene set. Moreover, 
the positive score that is added to the ES is weighted, that is, a higher score is added 
when a gene higher on the ranked list is found to be a member of the gene set than when 
a gene lower on the ranked list is marked with a hit. Therefore, a high ES means that the 
gene set is over-represented towards the top of the ranked list. The null hypothesis is 
that the genes belonging to certain gene sets are evenly spread throughout the ranked 
gene list. Significance of the GSEA was tested by permuting gene labels (1000 
iterations). Gene sets smaller than five were excluded from the analysis. 
 
According to the Minimum Information About Microarray Experiment (MIAME) 
recommendations, all the microarray data were published in the Gene Expression 
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/).  
 
Protein analysis 
In the papers of this thesis, we chose to validate the microarray results on protein levels 
rather than on gene level. By this approach, pathogenic mechanisms of disease, which 
involves protein modifications, are accounted for. Since we are interested in functional 
changes by alterations in gene expression, protein measurements may yield more 
insight. In this thesis, the level of mRNA correlated, in most cases, well with the 
quantity of proteins synthesised. We used three different approaches to obtain 
quantitative or semi-quantitative protein expression levels; immunohistochemistry, 
Western immunoblotting, and Enzyme-Linked ImmunoSorbent Assay (ELISA). 
 
Immunohistochemistry 
Immunohistochemistry refers to the process of localizing proteins in cells of a tissue 
section, exploiting the principle of antibodies binding specifically to antigens in 
biological tissues. The proteins are localized with specific antibodies that are visualized 
by different detection systems. The detection systems are constantly improving, and 
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today, they allow for protein detection several months/years after the process was 
conducted. Immunohistochemistry allows for semi-quantitative detection of protein 
levels in tissue. Disadvantages with immunohistochemistry involve possibilities of 
background staining and masked epitopes by the fixation procedure.  
 
Western immunoblotting 
Western immunoblotting allows for semi-quantitative detection of a specific protein in a 
given sample of tissue homogenate. Denatured proteins are separated by the length of 
the polypeptide and electrophoresed prior to the protein detection. Proteins are then 
transferred to a nitrocellulose membrane, where they are detected using specific 
antibodies and chemiluminecence. Due to many steps in this protocol, optimizing of all 
the different steps is needed to obtain good reliable results. Disadvantages of this 
method include the fact that immunoblotting is time consuming and mainly a qualitative 
assay. 
 
ELISA 
The ELISA technique has a high sensitivity and can detect the amount of a given 
protein, antibody, or antigen in a sample. In addition to being used as a diagnostic tool 
in medicine and research, ELISA is also being used in plant pathology, as well as a 
quality control check in various industries. In simple terms, an antibody for a specific 
protein is fixed to the surface in a well. The specific protein binds to the antibody in the 
well, where it is attached. Then a second antibody is added, which binds to another site 
on the protein. This antibody is linked to an enzyme, which is converted to some 
detectable signal as the final solution is added. Today, most of the commercial ELISAs 
are based on fluorescence, due to the high sensitivity of the fluorogenic substrates. 
ELISA allow for quantitative detection of protein level in blood. Disadvantages with 
ELISA is the limited numbers of commercial available assays, and high purchasing 
costs.    
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Statistics 
Microarray statistics constitute its own discipline in the field of statistics. It is complex 
and under constant development. Due to the vast amount of data created in each single 
microarray run, statistical tests that accounts for multiple testing is needed. Regarding 
the other results presented in this thesis, non-parametric procedures are the most 
appropriate, since each study operates with a limited number of animals and patiens per 
group.   
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Summary of the results 
 
Paper I: Before the exercise intervention, the sedentary LCR and HCR rats differed 
significantly in VO2max (30% higher in HCR), cardiomyocyte contractility and Ca2+ 
handling. Exercise improved all these three parameters in both HCR and LCR. In 
sedentary untrained rats, gene expression analysis of the LV from HCR and LCR 
revealed 1540 differentially expressed transcripts. Enlarged cardiomyocytes (33% 
wider) and upregulation of embryonic growth factors indicated ongoing pathological 
growth in sedentary LCR. In addition, LCR expressed high levels of genes associated 
with cellular stress, and low levels of contractility regulating genes and cholesterole 
lowering agents. The sedentary LCR also expressed higher amounts of genes involved 
in glucose metabolism, and less of the genes involved in lipid metabolism, as compared 
to the sedentary HCR. Hypoxic conditions seemed to be a common source for several of 
these observations, indicated by the switch in energy substrate metabolism, upregulation 
of hypoxia-induced growth factors, and enhanced expression of genes associated with 
DNA damage. No exercise-induced changes in LV gene expression were detected in 
either of the groups. 
 
Figure 3. Heat map of the 100 most differentially expressed transcripts in Paper I. HCR-TR: Exercise-
trained high capacity runners, HCR-SED: Sedentary high capacity runners, LCR-TR: Exercise-trained 
low capacity runners, LCR-SED: Sedentary low capacity runners. 
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Paper II: Before the exercise intervention, the sedentary LCR and HCR rats differed 
significantly in running speed at VO2max (120% higher in HCR). In both HCR and LCR, 
8 weeks of exercise training induced almost equal improvements in running speed, as 
compared to the sedentary counterparts. Fibre typing of the soleus muscle revealed a 
trend (P=0.07) towards less fast fibres after exercise in the HCR group. In sedentary 
untrained rats, gene expression analysis of the soleus muscle from HCR and LCR 
revealed only three differentially expressed transcripts. LCR expressed high levels of a 
transcript with strong homology to human leucyl-transferRNA synthetase 2 (LARS2). 
Upregulation of this gene in humans has previously been associated with a 
mitochondrial mutation linked to maternally inherited diabetes and mitochondrial 
dysfunction. The response to exercise seemed more pronounced in HCR than LCR, in 
terms of gene expression. A transcript similar to the cytochrome c oxidase VIIa was 
upregulated after exercise in both groups. In HCR, the adaptation to exercise affected 
genes involved in FA metabolism, FA elongation in the mitochondria, in addition to 
genes located in the peroxisomes. Endurance training also seemed to involve different 
structural adaptations and differences in improvements of fibrinolytic potential in 
skeletal muscle dependent on the inborn VO2max. 
 
Figure 4. Heat map of the 150 most differentially expressed transcripts in Paper II. HCR-T: Exercise-
trained high capacity runners, LCR-T: Exercise-trained low capacity runners, LCR-S: Sedentary low 
capacity runners, HCR-S: Sedentary high capacity runners. 
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Paper III: Eleven metabolic syndrome patients performing 16 weeks of aerobic interval 
training, significantly reduced their risk of CVD, in terms of improved VO2max (+35%), 
endothelial function (+10%), mean arterial blood pressure (-5%), insulin sensitivity, 
fasting glucose and plasma lipid composition. Additionally, after the training period, 
47% of the patients were no longer classified as having the metabolic syndrome. Gene 
expression analysis of blood cells from these patients revealed 18 biological processes 
and molecular functions altered by interval training. Eleven processes and functions 
were upregulated after exercise, including e.g. steroid hormone-mediated signaling. 
Seven processes and functions were downregulated after exercise, which included e.g. 
blood clotting, cell adhesion and steroid metabolism. Downregulation of arginase 1 and 
von Willebrand factor (VWF) was confirmed at protein level.  
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Figure 5. Biological processes and molecular functions significantly altered by exercise in metabolic 
syndrome patients. CAM: Cell adhesion molecule. 
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Discussion 
Inborn low VO2max was associated with a gene expression profile indicating LV 
pathological hypertrophy, contractile dysfunction, cardiac stress, abnormal cardiac 
metabolism, cardiac inflammation, and skeletal muscle mitochondrial dysfunction. The 
LCR gene expression profile resembled a compensatory mechanism for an inefficient 
heart. These features are likely to contribute to the low inborn VO2max and accumulation 
of risk factors related to CVD.  
 
The gene expression profile of exercise-adaptation in skeletal muscle was more 
pronounced in individuals with inborn high VO2max, as compared to the individuals with 
low VO2max. In the heart, no exercise-induced changes in gene expression were found at 
the time of sample collection. In patients with low VO2max and the metabolic syndrome, 
the blood gene expression profile indicated an exercise-induced downregulation of 
genes associated with endothelial dysfunction, blood clotting, and atherosclerosis.   
 
The gene expression profile of inherited high- and low VO2max 
Recently, the HERITAGE Family Study investigated the role of genes in determining 
inborn VO2max133. They found familial resemblance for VO2max, and suggested that both 
genetic and environmental factors were involved. The heritability was estimated to 
account for 47% of the VO2max. Interestingly, a significant maternal effect was 
observed, potentially associated in part with mitochondrial inheritance. These results 
suggest that genetic and non-genetic factors, as well as maternal influences contribute to 
the familial aggregation of VO2max in sedentary individuals.  
 
Pathological hypertrophy 
When studying the cardiac phenotype and gene expression pattern of sedentary LCR 
rats, we found several signs of pathological growth. LCR cardiomyocytes were 33% 
wider than HCR myocytes, which indicates hypertension-induced hypertrophy, in line 
with a higher blood pressure in LCR134. Upregulation of genes associated with 
embryogenesis further supported ongoing pathological growth in LCR LV, as 
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embryonic growth factors are common features in pathological cardiac hypertrophy135, 
136. These results imply that a genetic predisposition is sufficient to induce pathological 
cardiac growth in relatively young subjects (7 months old).  
 
A common feature in cardiac growth is angiogenesis. During the acute phase of cardiac 
growth, angiogenesis is normally enhanced, but as the heart enters the chronic phase of 
pathological remodelling, angiogenesis is usually impaired. This disruption of 
coordinated growth and angiogenesis is a contributing factor to the transition to HF137. 
Interestingly, genes promoting angiogenesis were less expressed in LCR compared to 
HCR, which may lead to reduced O2 and substrate delivery to cardiomyocytes, and 
contractile dysfunction. This suggests that the pathological growth in LCR might be 
past the acute phase and is progressing towards HF. The previously reported systolic 
and diastolic dysfunction in LCR also suggests a possible transition towards HF in these 
animals107. 
 
Contractility regulating genes 
Sustained pathological hypertrophy may lead to systolic and diastolic dysfunction, in 
line with the previously reported impaired contractility and Ca2+ handling in LCR 
cardiomyocytes22, 107. Ca2+ characteristics similar to those reported in LCR, are also 
found in diabetic rats, and in rats with HF62, 64, 138. Two genes that regulate heart rate 
and contractility were among the most differentially expressed genes in the LV of HCR 
and LCR. Both CD38 and the inward rectifying potassium (K+) channel (subfamily J, 
member number 3) were less expressed in LCR compared to HCR. Less inward K+ 
channels in LCR will potentially lower the myocyte membrane potential, hence making 
the myocytes from LCR more susceptible to delayed after-depolarization and 
ventricular tachyarrhythmia, which was recently reported in these rats110. Reduced 
density of inward rectifying K+ channels and a lower resting membrane potential have 
been reported in HF139. CD38 is responsible for most of the synthesis of cyclic-ADP-
ribose in the myocardium, which in turn controls the Ca2+ homeostasis in cardiac 
myocytes. Cyclic-ADP-ribose enhances the sensitivity of ryanodine reseptors governing 
the Ca2-induced Ca2 release from the SR, and thus the contraction140. This coincides 
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with the previously reported lower Ca2+ transient and contractility in LCR myocytes22, 
107. Genes causing depressed contractility may influence SV and contribute to a reduced 
VO2max in LCR. 
 
Cardiac metabolism 
The microarray data suggested that long-term selection for VO2max resulted in different 
cardiac energy metabolism. LCR expressed low amounts of genes involved in lipid 
metabolism, and high amounts of genes involved in glucose metabolism, suggesting that 
LCR hearts rely more on glucose as an energy substrate, than lipids.  
 
Differences in cardiac energy metabolism in HCR and LCR may be explained by the 
different compositions of energy substrates delivered to the heart, as LCR have elevated 
plasma levels of glucose, triglycerides, and FFAs as compared to HCR22. This means 
that LCR and HCR hearts have access to different pools of potential energy substrates, 
which may result in adaptation of enzymes metabolizing these different substrates. As 
previously mentioned, the heart metabolizes whatever substrate offered by the 
circulation at a certain time point. The different cardiac energy metabolism might also 
be a result of an underlying pathology within the myocardium. For instance, both 
humans and rats with hypertension-induced cardiac hypertrophy have decreased 
myocardial uptake, utilization, and oxidation of FAs141, 142. In fact, changes in cardiac 
energy substrate utilisation, from normal mitochondrial FAO to glucose oxidation are 
commonly seen in diseased hearts76. The changes are then often triggered by a 
downregulation of enzymes involved in FAO, as reported in LCR. Since the amount of 
ATP produced per O2 consumed is higher in glucose oxidation than FAO, such 
adaptations will initially relieve the energy deficiency. However, as the condition 
progresses towards an uncompensated state, the capacity of utilizing glucose 
decreases77.  
 
One of the genes potentially involved in decreased FAO in LCR is carnitine 
palmitoyltransferase 1α (Cpt1α). The long-chain FA transporter Cpt1α was 29 % more 
expressed in HCR compared to LCR, and governs the most important and rate limiting 
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step in mitochondrial FAO143. As insulin is a potent inhibitor of Cpt1α transcription, the 
previously reported hyperinsulinemia in LCR may explain the downregulation of 
Cpt1α143, 144. A clear correlation between Cpt1 mRNA concentrations and measured 
CPTI activity has previously been reported; hence, LCR are likely to have a lower 
CPT1α activity than HCR144. Since, CPT1 is crucial in regulating myocardial FAO145, 
insulin-inhibition of this enzyme in LCR represents a potential reason for impaired 
removal of circulating FAs, less FAO and hence, cardiac energy deficiency. A potential 
course of events in the heart of LCR is illustrated in Figure 6.  
 
 
Figure 6. A potential course of events in the heart of LCR. Cpt1α: Carnitine palmitoyltransferase 1α, 
FAO: Fatty acid oxidation.  
 
 
A potential compensation for impaired FAO in LCR is the upregulation of ATP 
synthase (mitochondrial F1 complex). ATP synthase (mitochondrial F1 complex) is an 
important component of Complex V and a rate-limiting step in the electron transport 
chain (Figure 7). This situation is often seen in HF, and might be a compensatory 
mechanism to meet increasing energy demands53.   
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Figure 7. Schematic illustration of the electron transport chain. H+: Hydrogen ion, e-: Electron, O2: 
Oxygen, H2O: Water, ADP: Adenosine diphosphate, ATP: Adenosine triphosphate.  
 
 
In contrast to decreased expression of genes involved in FAO, we found a evident 
upregulation of several genes regulating glucose metabolism in the LV of LCR rats. 
Increased glucose metabolism was indicated by the high expression of three important 
glycolytic enzymes, hexokinase 2, 6-phosphofructo-2-kinase, and glyceraldehyde 3-
phosphate dehydrogenase (Gapdh), catalyzing reaction one, two, and six in the 
glycolysis respectively. Reaction number two, irreversibly catalyzed by 6-
phosphofructo-2-kinase, is subject to extensive regulation, because the original substrate 
is forced to proceed down the glycolytic pathway after this step. This leads to a precise 
control of glucose, galactose and fructose going down the glycolytic pathway. Before 
this reaction, glucose-6-phosphate can potentially travel down the pentose phosphate 
pathway, or be converted to glucose-1-phosphate and polymerized into the storage form 
glycogen. Moreover, LCR expressed high amounts of the transcription factor kruppel-
like factor 15 (Klf15), which regulate the expression of genes involved in glucose 
uptake, such as glucose transporter 4 (Glut4)146. In addition to the previously possible 
explanations for metabolic differences between HCR and LCR, increased expression of 
glycolytic enzymes may also be a compensatory mechanism of insulin resistance. 
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Hypoxia-induced transcription 
Several of the genes upregulated in the LV of LCR indicated that hypoxia-induced 
transcription was responsible for some of the pathological features. Upregulation of 
genes involved in glucose metabolism (hexokinase 2, 6-phosphofructo-2-kinase, 
Gapdh), glucose transport (Klf15), growth (fibroblast growth factor 1, platelet-derived 
growth factor 1 α), cellular stress (DNA damage inducible transcript 4), as well as 
downregulation of genes involved in FAO, are triggered by the hypoxia-inducible 
transcription factor 1α (HIF1α) (Figure 8)147-150. Hypoxia-induced transcription occurs 
when low levels of O2 are detected in the tissue, and involves upregulation of genes 
responsible for increase in O2 delivery and survival during hypoxia. HIF1α is actually 
one of the few transcription factors promoting upregulation of the glycolytic 
pathway147. The reduced cardiac contractility, as well as the previously reported 
impaired O2 supply, extraction ratio, and tissue diffusion capacity in LCR, support our 
findings of hypoxia-induced transcription106, 113.  
 
  
Figure 8. Genes that were among 
the most upregulated in sedentary 
LCR compared to sedentary HCR, 
and that are inducible by hypoxia-
induced factor 1 α. HIF1α: 
Hypoxia-induced factor 1α, Klf15: 
Kruppel-like factor 15, Hk2: 
Hexokinase 2, Gapdh: 
glyceraldehyde 3-phosphate 
dehydrogenase, Pfkfb2: 6-
phosphofructo-2-kinase, Fgf1: 
Fibroblast growth factor 1, Pdgf1α: 
Platelet-derived growth factor 1α, 
Ddit4: DNA damage inducible 
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Skeletal muscle metabolism 
Based on the number of genes being differentially expressed, differences related to 
inborn levels of VO2max seemed to be much more pronounced in the heart, than in 
skeletal muscle. Interestingly, Gonzalez et al reported that skeletal muscles were the 
main reason for the higher VO2max in HCR compared to LCR at generation 790. Based 
on our findings, it seems like the heart also contributes significantly to the difference in 
VO2max when the artificial selection has reached generation 16. This is also in line with 
recent findings by Gonzalez et al based on rats from generation 15, that continuing 
divergence in VO2max between HCR and LCR occurs largely as a consequence of 
changes in the capacity to deliver O2 to the exercising muscle106. 
 
In the soleus muscle of LCR, proteins required for mitochondrial biogenesis and 
function has previously been reported to be downregulated22. At the gene level, 
however, only three transcripts were found differentially expressed in the soleus muscle 
of HCR and LCR. This suggests that post-transcriptional processes, including 
translation regulation is different in LCR and HCR. One of the transcripts that were 
significantly more expressed in LCR than HCR, had a strong homology with the 
mitochondrial LARS2 seen in humans. Upregulation of the human homolog is regarded 
as a hallmark of a mitochondrial DNA A-to-G point mutation in the leucyl-transferRNA 
(tRNA)Leu (UUR) gene at base pair 3243151. The mutation generates structural and 
functional defects of the tRNALeu (UUR), including impaired aminoacylation, reduced 
half-life, and/or decreased steady-state level152-154. Since tRNALeu (UUR) is involved in 
the construction of proteins, such a mutation will cause translation dysfunction of the 
UUR leucine codons and lead to a disruption of intra-mitochondrial protein synthesis152. 
This will influence on protein synthesis of the 13 subunits of complexes I, III, IV and V 
in the electron transport chain, which will decrease respiration and O2 consumption 
(Figure 7). This mutation is heteroplasmic (the percentage of mutated DNA vary 
between tissues), and causes maternally inherited diabetes and mitochondrial 
dysfunction155, 156. Humans suffering from this mutation are diagnosed with the disorder 
“Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes” 
(MELAS). The syndrome is associated with insufficient O2 extraction from blood, 
decreased activity of complex I (Figure 7), and reduced mitochondrial ATP production. 
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These malfunctions leads to hyperglycaemia, muscle weakness, high resting and 
exercise-induced lactate concentrations, increased fatigability, and exercise 
intolerance155, 157, 158. Several of these symptoms are previously reported in LCR22, 106-
108, 111, 113. In line with our findings, a growing body of evidence suggests that, compared 
to HCR, LCR have compromised mitochondrial function22, 109, 112. In LCR, this might be 
a contributing factor to the low inborn VO2max and the metabolic syndrome. 
Interestingly, only a short period of exercise training remarkably increases the ratio of 
wild type–to–mutant DNA and the proportion of muscle fibres with normal respiratory 
chain activity159. For this reason, endurance training might be particularly important for 
LCR. 
 
Because of the strong link between low VO2max and the metabolic syndrome, the 
tRNALeu (UUR) mutation should be further studied as a possible CVD risk factor. Subjects 
diagnosed with MELAS are associated with increased CVD risk; however, as the ratio 
of wild-type-to-mutant DNA varies, asymptomatic subjects might also carry the 
mutation. New technology has made it possible to detect this mutation by analysing 
blood samples, which makes it feasible to study the connection between the tRNALeu 
(UUR) 3243 A→G mutation and CVD risk in a large population160.  
 
Blood lipid status 
We have previously reported high levels of plasma triglycerides and FFAs in LCR 
compared to HCR22. From our microarray analysis, cholesterol-lowering agents as the 
VLDL receptor and colony-stimulating factor 1 (Csf1) were both less expressed in LCR 
compared to HCR76, 161-163. Administration of CSF1 has been tested as a potential 
therapy for hypercholesterolemia, and favourable results have been reported164. Low 
expression of Csf1 and the VLDL receptor might contribute to the reported 
accumulation of serum triglycerides and FFAs in LCR.  
 
Another potential reason for high serum levels of glucose and FA in LCR was their low 
expression of uncoupling protein 4 (Ucp4). Previous studies have reported that 
uncoupling proteins are involved in thermoregulation, metabolism, and obesity165-168. 
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Uncoupling proteins create proton leaks across the inner mitochondrial membrane, thus 
uncoupling oxidative phosphorylation from ATP synthesis. As a result, energy is 
dissipated in the form of heat, which diminishes ATP production, forcing the cells to 
oxidize more nutrients to obtain energy. In LCR, a low expression of Ucp4 may 
contribute to less glucose and FFAs disposal from the circulation. Acceleration of 
mitochondrial respiration, via induced uncoupling protein activity in appropriate tissues, 
has previously been suggested as a pharmacological target to counteract obesity169. 
 
The gene expression profile of acquired VO2max  
In the soleus muscle, significant transcriptional changes occurred in response to exercise 
training in both HCR and LCR. However, the changes were much more pronounced in 
HCR than LCR, indicating a substantial difference in the ability of transcriptional 
adaptation to exercise. Less genes upregulated by exercise in LCR is either a result of 
inborn genetic factors or running speed during the exercise bouts (less mechanical 
stress), since LCR were unable to maintain the same absolute speed as HCR, although 
working out at the same relative intensity170.  
 
In the LV, no annotated genes were differentially express after exercise training in 
either of the groups, despite improved contractility, Ca2+ handling, and VO2max. 
Originally, we expected to find upregulation of structural genes involved in 
physiological LV hypertrophy, as cardiac growth has been shown to persist beyond 
eight weeks of training by this type of exercise36.  
 
In both LV and the soleus muscle, the low number of genes induced by exercise may 
also be due to the chosen time of sample collection. Since the plateau of VO2max is 
reached a week or two before sample collection, genes augmenting VO2max might no 
longer be induced36.  
 
Since exercise has more pronounced effect on gene expression in animals born fit, it 
seems likely that some of the genes that determine inborn VO2max also determine the 
potential of training induced adaptations. This means that the LCR may be equipped 
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with a set of genes similar to the 10-15 % of humans that have little or no effect of 
exercise training, in terms of VO2max171, 172. Interestingly, we are about to establish new 
rat lines that are either high or low responders to training. These rats may be helpful to 
identify whether the “high responder genes” are similar to those observed in HCR.  
 
Structural adaptations 
Endurance training seemed to involve different structural adaptations in skeletal muscle 
dependent on the inborn VO2max. After endurance training, LCR expressed significantly 
more of the negative regulator of growth “A Disintegrin and Metalloproteinase with 
ThromboSpondin motifs 1 (Adamts1). Upregulation of Adamts1 is associated with 
muscle weakness, muscle wasting, and various inflammatory processes173. Hence, 
upregulation of Adamts1 in the soleus muscle of LCR suggests an ongoing 
inflammatory process and impaired growth.  
 
Another regulator of growth, Igf1 was significantly more expressed in the soleus muscle 
of exercise trained LCR than exercise trained HCR. IGF1 plays a major role in exercise-
induced skeletal muscle hypertrophy and strength improvements. IGF1 is highly 
inducible with exercise, and the level often keeps increasing the two following days 
after one single exercise bout174 At first, a higher exercise-induced increase in Igf1 
mRNA in the LCR group compared to the HCR group was not easily explained. 
However, when performing Western blot, we found twice as much IGF1 in the 
sedentary HCR compared to the sedentary LCR. That is, the LCR had a considerably 
lower basis of IGF1 before the exercise intervention. Reduced levels of IGF1 have 
previously been reported in HF175, 176. Skeletal muscle IGF1 levels correlate with 
muscle cross-sectional area, and low levels of IGF1 may contribute to the development 
of muscular dysfunction and atrophy175. The low levels of IGF1 in sedentary LCR may 
originate from a GH deficiency, and may contribute to impaired running speed and 
VO2max. The potential for exercise-induced increase in IGF1, by means of work-
overload and passive stretch, does however seem to be maintained in LCR. The reason 
why exercise had no impact on the IGF1 levels in the HCR group remains unknown. 
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Surprisingly, the mRNA level of myosin heavy-chain 4 was 34-times upregulated after 
endurance training in HCR. Upregulation of this fast-twitch myosin might cause a shift 
in fibre type towards more fast fibres. However, when performing fibre-typing of 
formalin-fixed soleus muscles, there were no signs of an increased number of fast fibres 
in exercise-trained HCR, but rather a trend towards less fast fibres (P=0.07). In line with 
our results from the fibre typing, stimuli like endurance training most often result in a 
shift from fast to slow fibres. The reason for exercise-induced upregulation of myosin 
heavy-chain 4 in HCR remains unknown.    
 
Skeletal muscle metabolism 
Several genes associated with metabolism were upregulated in the skeletal muscle of 
HCR after exercise training, indicating a normal adaptation to increased workload. The 
tendency of less fast fibres after the exercise intervention in these animals also points 
towards a more pronounced effect of the exercise program and a greater potential of 
improving O2 consumtion in the skeletal muscle, as compared to LCR. As the VO2max of 
LCR is limited both by the heart (reduced SV) and by O2 extraction in skeletal muscle, 
this may restrict the muscular adaptations to exercise106, 113. Even so, in both HCR and 
LCR, exercise upregulated a transcript similar to the cytochrome c oxidase (Cox) VIIa 
(a subunit of Complex IV in the electron transport chain). Increased transcription and 
translation of different COXs is a common feature of exercise training, and a marker of 
mitochondrial content and biogenesis177, 178. 
 
Accumulating evidence indicate that exercise-trained muscles oxidize more FAs, both 
during and after exercise179-181. Consequently, glycogen stores are spared, 
hypoglycaemia-induced fatigue is delayed, and exercise capacity is increased180, 181. A 
variety of processes, like lipolysis, lipid delivery, lipid transport across membranes, 
lipid transport within the cell, and FAO, could contribute to the increase in fat 
disposal180, 182. In HCR, we found indications of increased FA metabolism after 
exercise, represented by upregulation of genes like carnitine o-octanoyltransferase 
(Crot) and enoyl CoA hydratase (Auh). Crot is important for the transfer of chain-
shortened FAs from the peroxisomes to the mitochondria, making more FAs available 
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for mitochondrial FAO183. There is controversy whether CROT contributes to enhanced 
FAO in skeletal muscle with exercise training. A previous study concluded that CROT 
was not involved in increased FAO with exercise training184. However, they argued that 
the muscle studied (vastus lateralis), might have been unable to reflect the training 
adaptations induced by distance running to a similar degree as compared to another 
muscle group such as the gastrocnemius. Furthermore, the increased expression of the 
FAO enzyme Auh indicates increased energy production in the mitochondria. Since 
mechanisms responsible for enhanced FAO in exercise-trained muscle are not 
completely elucidated, both Crot and Auh should be further studied to elucidate their 
role in skeletal muscle FAO after exercise. 
 
Interestingly, genes regulating FA elongation in mitochondria, and genes belonging to 
the peroxisomes were significantly upregulated by exercise in the soleus muscle of 
HCR. Peroxisomes have largely been overlooked with respect to maintaining a healthy 
cellular lipid environment in the cells. Peroxisomes are ubiquitously expressed and have 
a wide range of cellular functions, including a primary role in FAO185. Since 
peroxisomes can oxidize all types of FAs, whereas the mitochondria oxidizes only short 
chain FAs; increased peroxisomal activity might be important for enhanced FAO in 
exercise-trained muscle. 
 
The only gene downregulated by exercise in HCR was adenylate cyclase 6 (Ac6). AC6 
is a membrane-associated enzyme that catalyzes the formation of cyclic adenosine 
monophosphate (cAMP). cAMP promotes intracellular glucose production and inhibits 
the expression of GLUT4, and thus obstructs glucose transport into the muscle186. 
Downregulation of Ac6 in exercise-trained HCR and a probable decrease in cAMP may 
therefore enforce expression of GLUT4, which is a common feature of endurance 
training and important for maintaining normoglycemia187. Mechanisms that regulate the 
expression of GLUT4 are important targets in the treatment of hyperglycaemic 
disorders as diabetes; for this reason, Ac6 should be further studied as a possible trigger 
of improved health by exercise.  
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Endothelial function 
Endothelial dysfunction is an early pathogenic event of the metabolic syndrome that 
often appears decades before the onset of vascular disease98. It is characterized by 
reduced bioavailability of NO that arises from decreased production or increased 
degradation of NO, or both. Regular endurance training, however, has the potential of 
effectively restoring endothelial dysfunction and NO bioavailability in metabolic 
syndrome patients11, 188. For the exercise trained metabolic syndrome patients (Paper 
III), improved endothelial function was accompanied by decreased expression of 
arginase 1, increased expression of genes associated with steroid hormone signalling, as 
well as decreased transcription of cell adhesion molecules (CAMs). All these changes 
are potential contributors to the improvements seen in endothelial function. Blood levels 
of arginase 1 were significantly decreased by the exercise intervention, both at gene and 
protein level. Arginase is present in endothelial cells, erythrocytes, lymphocytes and 
neutrophils, and catalyzes the conversion of L- arginine to L-ornithine and urea. A high 
level of arginase decreases the availability of L-arginine for NO synthesis, and has 
previously been associated with endothelial dysfunction in aging189, 190. Decreased 
levels of arginase 1 after exercise may lead to increased levels of L-arginine, and thereby 
increased NO bioavailability, as in line with the previously reported trends (P=0.07) 
towards increased levels of NO in blood after endurance training in these patients11, 191. 
Downregulation of arginase 1 may therefore contribute to improved endothelial function 
and CVD risk profile. As NO contributes considerably to exercise-induced increase in 
limb blood flow, increased levels of NO may also be involved in increased VO2max in 
these patients192. 
 
Another common feature in endothelial dysfunction is inflammation. Activated 
endothelial cells increase their expression of CAMs, which further enhances the 
inflammation response193. Carcinoembryonic antigen-related CAM 5 and 
carcinoembryonic antigen-related CAM 8 (CD66B) were both downregulated in the 
blood of metabolic syndrome patients after exercise. High levels of CD66B has 
previously been associated with leukocyte activation, atherosclerosis and type 2-
diabetes194, 195. Exercise-induced decrease in CD66B transcription suggests improved 
vascular conditions and a reduction in factors contributing to endothelial inflammation. 
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Further studies should be carried out to determine the clinical potential of CAMs as 
potential sensitive and early markers of endothelial dysfunction.  
 
Another potential candidate for improved endothelial function by exercise, is the 
estrogen receptor β (ERβ). It is well known, that middle-aged women are much less 
likely than men to develop CVD, and that the difference is mainly estrogen mediated. 
Although the atheroprotective effects of estrogen are well recognized, the underlying 
mechanisms responsible are still not well understood. Interestingly, we found increase 
expression of the ERβ after exercise in metabolic syndrome patients. ERβ is expressed 
in the vasculature of both men and woman, and mediates nearly all of the known 
biological effects of estrogen196. Recently, increase estrogen receptor-signalling has 
been suggested to counteract CVD through beneficial effects on blood pressure, 
endothelial function, plasma lipids composition, antioxidant system, coagulation system, 
and carbohydrate and lipid metabolism197-201. Endothelial effects of estrogen receptor-
signalling involves increased NO production in the vasculature, through increased 
expression and activation of endothelial NO synthase. This is in line with the earlier 
discussed trends (P=0.07) towards increased level of NO in blood after endurance 
training11. Increased expression of ERβ  therefore potentially contributes to the 
improved CVD risk profile seen after endurance training. 
 
Blood clotting 
Each of the risk factors that constitute the metabolic syndrome appear to uniquely 
promote atherosclerosis; yet, the mechanism is not fully understood202. Increased levels 
of pro-thrombotic factors is not included in the diagnostic criteria, however, metabolic 
syndrome patients often suffer from both an impaired coagulation system and platelet 
function13. Regular physical exercise has proved effective in restoring the haemostatic 
imbalance in individuals with CVD risk factors102, 103. This is in line with our findings, 
as genes controlling blood clotting, like coagulation factor XIII, thrombin, VWF, 
integrin 3β and gamma-glutamyl carboxylase were less expressed in metabolic 
syndrome patients after long-term endurance training.  
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VWF is an important biomarker of endothelial damage and dysfunction, and has strong 
correlation to diabetes and CVD203-206. In metabolic syndrome patients, endurance 
training reduced both mRNA and protein level of VWF in plasma. As estrogen is a 
potential inhibitor of coagulation factor transcription, the increased expression of 
ERβ might be involved in reduction of VWF and other coagulation factors after 
exercise207. Decreased transcription of pro-thrombotic factors is likely to contribute to 
the improved vascular function and CVD risk profile observed in metabolic syndrome 
patient after 16 weeks of exercise. 
 
Increased fibrinolytic potential is a well-known beneficial effect of long-term endurance 
training, as large amounts of clot-destroying fibrinolytic proteins are produced by the 
exercise-trained muscles14, 102. When comparing soleus muscle gene expression after 
exercise in HCR and LCR, HCR expressed less fibrinogen-like 2, a recently discovered 
pro-thrombinase208. The superior fitness in exercise-trained HCR may contribute to a 
superior anti-thrombotic status, as compared to LCR. 
 
Study limitations 
We were unable to fully determine whether the differential gene expression patterns 
reported in Paper I and Paper II represent the cause or the consequence of the inborn 
differences in VO2max. Further follow-up studies with modification of particular genes 
are needed for this purpose.  
 
In Paper III, the small number of patients makes it difficult to draw definite conclusions; 
hence, further studies are needed to verify our findings in a larger population. The low 
number of patients has also made it hard to detect group differences, due to paired-
samples statistics. 
 
Further perspectives 
While gene expression profiling do not tell the whole story of what might be happening 
in your sample, metabolic profiling (metabolomics) can give an instant snapshot of the 
physiology of the cell. Metabolomics is a systematic study of the unique chemical 
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fingerprints that a specific cellular processes leave behind in the form of small-molecule 
metabolites209. The metabolome represents the collection of all metabolites in a 
biological organism, which are the end products of the gene expression. To give a more 
complete picture of the biology of a sample, gene expression profiling and 
metabolomics should be integrated in future studies.  
 
Since a growing number of genes are associated with risk factors of CVD, as low 
VO2max and the metabolic syndrome, we are getting closer to finding new possible drug 
targets of these pathological conditions. Also by studying exercise-induced changes in 
gene expression in these patients, we can get an indication of which genes that mediates 
the beneficial effects of exercise. Therefore, screening the entire genome for changes in 
gene expression may lead to the discovery of new pharmacological drug targets of these 
complex diseases. Recently, a new promising treatment strategy involving RNA 
interference (RNAi) has emerged. RNAi is a naturally occurring mechanism that 
suppresses the expression of a specific gene and provides potential for treatment of the 
metabolic syndrome, e.g. reducing plasma cholesterol levels210, 211. RNAi is induced by 
small (21–23 nucleotides) homologous RNA molecules, like double-stranded small 
interfering RNA (siRNA) and single-stranded micro RNA. To further develop this 
treatment strategy, it is essential to define a set of candidate genes that are involved in 
the development and/or progression of the metabolic syndrome, as well as determining 
a safe delivery of the siRNA to the diseased tissue. We hope that some of the genes 
associated with risk factors of CVD, and improvements with exercise reported in this 
thesis, may be potential candidates for the management of the metabolic syndrome.  
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Main Conclusions 
 
A. Rats born with different VO2max show a great difference in LV gene expression. 
The LV gene expression patterns associated with an inborn low VO2max involved 
activation of survival mechanisms to meet the body’s demands. First, the low 
VO2max is associated with upregulation of embryonic growth factors and 
increased cardiomyocyte width, which suggests pressure-induced pathological 
hypertrophy. Second, the low VO2max is associated with a metabolic switch from 
oxidation of FAs to glucose, thus improving the energy efficiency of the heart, 
e.g. in early stages of HF. Hypoxia-induced changes in transcription seem to be 
a common source for the cardiac adaptations associated with inborn low VO2max. 
Gene expression analyses of the soleus muscle indicated that inborn low VO2max 
is linked to a mitochondrial DNA mutation causing impaired translation of 
mitochondrial genes and metabolic dysfunction. In humans, such a mutation 
involves impaired O2 extraction from blood, hyperglycaemia, and exercise 
intolerance, which is in accordance with the previous reported characteristics of 
LCR. Because of the strong link between low VO2max and CVD, this DNA 
mutation should be further studied as a possible risk factor of CVD. 
 
B. The low VO2max and increased cardiovascular risk in LCR is probably a result of 
both impaired skeletal muscle function and impaired cardiac function. In the LV, 
genes that contribute to cardiac dysfunction, e.g. the embryonic growth factors, 
contractility regulating genes, and inflammatory factors may influence on the 
SV and hence VO2max. In the soleus muscle, the possible DNA mutation causing 
impaired translation of mitochondrial genes may result in less O2 consumption 
and energy production. The same genes that contribute to cardiac dysfunction 
will make the heart more susceptible to CVD. In addition, the potentially 
depressed mitochondrial function in skeletal muscles may cause accumulation of 
energy substrates, creating an unfavourable accumulation of nutrients in blood 
and inside the cells. Such conditions may contribute to vascular disease and 
increased CVD risk.  
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 C. Rats born with different VO2max respond differently to the same exercise 
protocol in terms of soleus muscle gene expression. The rats born with high 
VO2max upregulated several genes, and seemed to adapt well to exercise training. 
The rats born with a low VO2max seemed to be less adaptive to exercise training 
in terms of gene expression. In LV, no exercise-induced changes in gene 
expression were detected in either of the groups. The time of tissue collection, 
might be a contributing factor. 
 
D. Endurance training altered blood cell gene expression in subjects diagnosed with 
the metabolic syndrome. 16-weeks of high intensity interval training was 
sufficient to increase transcription of genes involved in steroid hormone-
mediated signalling, reduce the levels of arginase 1 and vWf, as well as reduce 
transcription of genes involved in cell adhesion, blood clotting and steroid 
metabolism. 
 
E. Decreased transcription of arginase 1 and several pro-thrombotic factors might 
be involved in exercise-induced improvements of endothelial function and 
cardiovascular risk profile of the metabolic syndrome patients. 
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  2 
Abstract 
Background: Regular physical activity has beneficial effects on the metabolic 
syndrome. Eleven metabolic syndrome patients performing 16-weeks of aerobic 
interval training, significantly reduced their risk of cardiovascular disease, in terms of 
improved VO2max, endothelial function, blood pressure, insulin signaling and plasma 
lipid composition. The knowledge on underlying mechanism of exercise-induced 
improvements is sparse, and a broad spectrum of methods is needed to gain more 
insight.  
Design: The aim was, for the first time, to determine whether transcriptional changes 
occurred in blood cells of metabolic syndrome patients after participating in an 
exercise program. 
Methods: Blood were collected on PAXgene and EDTA tubes before and after 16 
weeks of exercise. RNA was extracted and run on microarrays.  
Results: Eleven biological processes and molecular functions were upregulated after 
exercise, whereas seven were downregulated. Blood clotting, cell adhesion and 
steroid metabolism were among the downregulated processes, whereas steroid 
hormone-mediated signalling was upregulated. Downregulated protein levels of 
arginase 1 and von Willebrand factor confirmed microarray results. 
Conclusions: 16 weeks of exercise induced transcription of genes involved in steroid 
hormone-mediated signalling, decreased plasma levels of arginase 1, and reduced 
transcription of genes involved in cell adhesion, and blood clotting in metabolic 
syndrome patients. These changes are likely to be involved in exercise-induced 
improvements of endothelial function and the total cardiovascular risk profile. These 
findings have provided new insights on exercise-induced improvement of 
cardiovascular health, and may have important implications for exercise training in 
rehabilitation programs and for future studies. 
 
Abstract: 243 words 
 
Keywords: endothelial function, nitric oxide, cell adhesion molecules, microarray, 
RNA
  3 
Introduction 
The metabolic syndrome is defined as a cluster of factors that predispose for future 
cardiovascular disease (CVD) and includes hypertension, dyslipidemia, impaired 
glycemic control, and abdominal obesity [1]. Accumulating evidence indicate that 
regular physical activity has profound beneficial effects on the metabolic syndrome 
[2-5]. Recently, we demonstrated that aerobic interval training partly or fully reversed 
most of the factors that constitutes the metabolic syndrome, such as hypertension, 
insulin sensitivity, impaired glucose tolerance and dyslipidemia [6], in addition to 
improving endothelial function. In fact, 47% of the patients were no longer classified 
as having the metabolic syndrome after 16-weeks of exercise. Thus aerobic interval 
training seems to be an effective treatment strategy in patients with the metabolic 
syndrome. Despite this, the mechanisms behind exercise-induce improvements are 
unclear and specter of analytical methods are needed to better understand the 
beneficial effects of exercise training.  
 
Recently, promising results from gene expression studies, using high quality 
ribonucleic acid (RNA) isolated from whole blood have revealed unexplored fields of 
biomarker discovery and gene expression profiling of disease [7-10]. Due to easy 
accessible and minimally invasive sample collection, gene expression profiling of 
whole blood might turn out to be a promising tool in molecular diagnostics and 
clinical medicine. To our knowledge, whole-genome transcriptional changes have not 
previously been studied in metabolic syndrome patients undergoing a high intensity 
exercise program. We hypothesized that biological processes significantly altered by 
the exercise program, would include a set of genes at least partly responsible for the 
improvement seen in this patient group.  
  4 
Methods 
Patient group 
Eleven patients (7 males and 4 females) diagnosed with the metabolic syndrome, 
according to the WHO-criteria [1] were recruited to aerobic interval training. All 
subjects provided written, informed consent, and the regional ethics committee of 
medical research approved the protocol. Exclusions criteria were unstable angina, 
recent coronary arrest (≤4 weeks), uncompensated heart failure, severe pulmonary 
disease, uncontrolled hypertension, kidney failure, orthopedic and/or neurologic 
limitations, cardiomyopathy, pregnancy, drug or alcohol addictions, and participations 
in parallel studies. Detailed description of the patient population has recently been 
published [6] and their main characteristics are presented in Table 1. The investigation 
is conducted according to the principles expressed in the Declaration of Helsinki.  
  
Exercise program 
The participants performed aerobic interval training by walking or running “uphill” on 
a treadmill 3 times per week for 16 weeks. They warmed-up for 10 minutes at 70% of 
maximal heart frequency (Hfmax) before performing 4 intervals of 4 minutes at 90-95% 
of Hfmax, with 3 minutes of active recovery at 70% of Hfmax between each interval. In 
the end, they had a 5-minute cool-down period, giving a total of 40 minutes. 
 
Sample collection 
To avoid the acute effect of exercise, as changes in number and phenotype of 
circulating leucocytes [11], venous blood samples were collected 72 hours after the 
last exercise session. Blood were collected on PAXgene (Qiagen, Germantown, MD) 
and EDTA tubes (Vacuette, Kremsmuster, Austria) after 12-hours fast, at the same 
time of day for all patients, before and after the training period. The EDTA tubes were 
immediately centrifuged at 3000 rpm for 10 minutes, whereas the PAXgene tubes 
were handled according to manufacturer's instructions. All samples were stored at -80 
oC until assayed. 
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RNA isolation 
Total RNA was isolated from whole blood using the PAXgene Blood RNA Kit 
(Qiagen, Germantown, MD), and globin RNA was removed with GLOBINclear 
(Ambion, Austin, TX) according to the manufacturer's instructions. RNA integrity, 
purity and quantity were assessed by Bioanalyzer (Agilent Technologies, Santa Clara, 
CA) and Nanodrop (NanoDrop Technologies, Baltimore, MD). Only samples with a 
260/280 ratio between 1.8-2.2 and no signs of degradation were used for analysis. 
 
Microarray analysis 
RNA from five patients (3 males and 2 females) satisfied our strict requirement for 
high RNA quality. Samples from these patients were processed and hybridized to 
Applied Biosystem Human Genome Survey microarrays v.2.0. Raw-data was filtered 
and quantile normalized in J-Express Pro v.2.7 [12]. Signal intensities were log 
transformed and missing values were replaced by imputation using Adaptive 
LSimpute [13]. Genes with more than 10% missing values were rejected. Finally, 
probes were collapsed to genes, using Primary Gene ID from the Applied Biosystems 
Human Annotation File.  
 
Gene set enrichment analysis (GSEA) 
Genes were ranked from the most to the least significant, using the paired SAM 
(significance analysis of microarrays) statistical test, and used as an input to the 
GSEA[12] [14]. GSEA works by starting at the gene ranked on top of the gene list. If 
this gene is a member of a certain gene set, a positive score is added to an enrichment 
score (ES), otherwise a negative score is added. Then the next gene on the gene list is 
evaluated and the ES is updated. This process is repeated for every gene in the entire 
gene list. Therefore, a high ES means that the gene set is overrepresented towards the 
top of the ranked list. Significance of the GSEA was tested by permuting gene labels 
(1000 iterations). Gene sets smaller than five were excluded from the analysis. 
 
Gene sets were created using the Panther biological processes and Panther molecular 
functions (http://www.pantherdb.org). This information was extracted from the 
Applied Biosystem Human Annotation File, dated September 30th 2006.  
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Database submission 
The microarray data was prepared according to “minimum information about 
microarray experiment” (MIAME) recommendations, and deposited in the Gene 
Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) with accession 
number GSE10540.  
 
Enzyme-linked immunosorbent assay (ELISA) 
The plasma levels of arginase 1 and von Willebrand factor (vWf) were measured 
before and after the exercise period by Human Arginase 1 ELISA (Abnova, Taipei 
City, Taiwan) and Imubind vWf ELISA (American Diagnostica Inc, Stamford, CT) 
respectively. All samples were analyzed in triplicate according to the manufacturer's 
instructions. 
 
Statistics 
Due to a limited number of biological processes and molecular functions in our GSEA 
analysis, 151 and 147 respectively, processes and functions with a nominal P value 
below 0.05 were considered significant. To assess differences in plasma protein levels 
we applied the Wilcoxon Signed-Ranks Test in SPSS 14.0. P values below 0.05 were 
characterized as significant. All variations are shown as standard deviation.  
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Results 
Physiological characteristics of the patients in this study have previously been 
reported in detail [6]. An outline of these characteristics is summarized in Table 1. 
Shortly, the exercise-period induced a 35 % increase in aerobic capacity (VO2max), 10 
% improvement in endothelial function (in terms of flow-mediated dilatation in the 
brachial artery), 5 % reduction in mean arterial blood pressure, improved insulin 
sensitivity, increased levels of HDL, and reduced fasting glucose. Additionally, after 
the 16-week training period 47% of the patients were no longer classified as having 
the metabolic syndrome.  
 
Gene expression 
Out of 298 biological processes and molecular functions, eleven were upregulated 
after the exercise period (Table 2), and included processes involved in transcription, 
translation, and steroid signalling. Seven processes were downregulated after the 
exercise period (Table 2), and included blood clotting, steroid metabolism, cell 
adhesion molecules (CAMs) and amino acid catabolism. Decreased mRNA levels of 
arginase 1 and vWf after exercise contributed to the downregulation of the biological 
processes termed amino acid catabolism and blood clotting, respectively.  
 
Four biological processes were considered of special interest, regarding the previously 
reported exercise-induced, cardiovascular risk reduction and improved health status 
achieved by the metabolic syndrome patients. These processes included blood 
clotting, steroid hormone-mediated signalling, and amino acid, in addition to CAMs. 
Genes contributing their high ES are presented in Table 3.  
 
Protein expression 
The plasma protein levels of arginase 1 and vWf were measured to validate the 
microarray results. The protein levels of arginase 1 and vWf, were both found 
significantly lower after the exercise period (p<0.05) (Figure 1a and 1b), in line with 
the microarray data.       
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Discussion 
The main findings in this present study was that 16-weeks of exercise seemed to 
increase steroid hormone-mediated signalling, decrease the plasma levels of arginase 
1, and reduce transcription of genes involved in cell adhesion and blood clotting in 
patients diagnosed with the metabolic syndrome. We believe that these changes are at 
least partly responsible for the improved endothelial function and cardiovascular risk 
profile of the metabolic syndrome patients after the exercise period. 
 
Endothelial function 
Endothelial dysfunction is an early pathogenic event of the metabolic syndrome that 
often appears decades before the onset of vascular disease [15]. It is characterized by 
reduced bioavailability of nitric oxide (NO) that may arise from decreased production 
or increased degradation of NO, or both. Regular endurance training, however, has the 
potential of effectively restoring endothelial dysfunction and NO bioavailability in 
these patients [16] (Table 1). Arginase 1, which catalyzes the conversion of L- 
arginine to L-ornithine and urea, was less expressed after exercise in the metabolic 
syndrome patients. A high level of arginase decreases the L-arginine availability for 
NO synthesis, through endothelial NO synthase, and has been associated with 
endothelial dysfunction in aging [17, 18]. Decreased levels of arginase 1 after exercise 
may lead to increased levels of L-arginine, and thereby increased NO bioavailability 
[19], in line with the previously reported trends (p=0.07) towards increased level of 
NO in blood after exercise training (Table 1).  
 
Endothelial dysfunction often involves endothelial inflammation and activation. 
When endothelial cells are activated, they increase their expression of CAMs, which 
further promotes the inflammation response [20]. Carcinoembryonic antigen-related 
CAM (CEACAM) 5 and 8 were both downregulated after exercise. A high level of 
CEACAM8 has previously been associated with atherosclerosis, and type 2 diabetes 
[21]. Exercise-induced decrease in CEACAM8 transcription suggests improved 
vascular conditions and a reduction in factors promoting endothelial inflammation.  
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Another potential source of improved endothelial function is increased steroid 
hormone-mediated signalling after exercise. One of the genes responsible for the 
upregulation of steroid signalling was estrogen receptor β (ERβ), which is expressed 
in the vasculature of both men and woman [22]. Augmentation of estrogen mediated 
processes has beneficial effects on blood pressure [23, 24], endothelial function [25], 
plasma lipids composition [26], antioxidant system, coagulation system, carbohydrate- 
and lipid metabolism [27], as well as the levels of high-density lipoproteins (HDL) 
[26], which is in line with the findings in this study (Table 1). In the vasculature, 
increased ER-signaling also enhances NO production, which is in line with the 
previously reported trends (p=0.07) towards increased levels of NO in blood after 
exercise training (Table 1). Interestingly, as NO contributes considerably to exercise-
induced increase in limb blood flow [28], increased NO bioavailability through 
increased ER-signalling and decreased arginase 1 might contribute to the improved 
VO2max observed after the exercise period.  
 
Blood pressure 
Several studies agree that regular endurance training has beneficial effects on blood 
pressure [6, 29, 30], even so, the mechanism is not fully determined. Recently, mice 
lacking ERβ have been reported to be hypertensive [23]. Although this is an 
extremity, increased transcription of ERβ after the exercise intervention might be 
involved in lowering of blood pressure. Since increased ER-signaling and decreased 
arginase 1 may contribute to the increased NO bioavailability after the exercise 
period, both factors has the potential of reducing blood pressure through NO evoked 
dilatation of arteries and blood vessels. 
 
Blood clotting and atherosclerosis 
Each of the risk factors that constitute the metabolic syndrome appears to uniquely 
promote atherosclerosis [31]; yet, the mechanism is not fully understood. Increased 
levels of pro-thrombotic factors is not included in the diagnostic criteria, however, 
metabolic syndrome patients often suffer from both impaired coagulation system and 
platelet function [3]. Regular physical exercise has proven effective in restoring the 
haemostatic imbalance in individuals with CVD risk factors [32]. This is in line with 
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our findings, as genes controlling blood clotting, like coagulation factor XIII (fibrin 
stabilizing factor), thrombin, vWf, integrin 3β and gamma-glutamyl carboxylase were 
less expressed after the exercise training. vWf is a highly relevant biomarker of 
endothelial damage and dysfunction [33], and has a strong correlation to diabetes and 
cardiovascular disease [34, 35]. An inverse relationship between FMD and vWf has 
previously been reported in congestive heart failure patients [36], which, according to 
our results, also seems to be the case for metabolic syndrome patients. Estrogen 
therapy, increasing ER-signalling, has previously been associated with lower plasma 
concentrations of vWf and other coagulation factors [37]. Therefore, increased ER-
signalling may contribute to increased transcription of vWf and other coagulation 
factors after the exercise intervention.  
 
In conclusion, metabolic syndrome patients performing 16-weeks of high intensity 
interval training increased expression of genes involved in steroid hormone-mediated 
signalling, reduced the levels of arginase 1, as well as reduced transcription of genes 
involved in cell adhesion and blood clotting. These changes are likely to contribute to 
the exercise-induced improvements of endothelial function and total cardiovascular 
risk profile. Since the number of patients was low, further follow-up studies are 
needed to confirm these results in a larger patient population.
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Figure 
 
 
 
Figure 1: Plasma levels of Arginase 1 (ng/mL) and von Willebrand factor (vWf) 
(U/mL) in metabolic syndrome patients pre and post the exercise period.  
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Tables 
Table 1: Physiological characteristics of the patients[6]. 
 Interval training 
 Pre Post 
No. of patients with metabolic syndrome 11/11 6/11*
BODY COMPOSITION AND MAXIMAL OXYGEN UPTAKE   
Body weight, kg  91.8 ± 5.3 89.5 ± 4.9*
Body mass index, kg · m-2 29.8 ± 1.7 29.1 ± 1.5*
Waist, cm 105.5 ± 4.1 100.5 ± 3.6*
Maximal oxygen uptake, ml·kg-1·min-1 33.6 ± 2.5 45.3 ± 3.3**
ENDOTHELIAL FUNCTION AND BLOOD PRESSURE   
Flow mediated dilatation (%) 3.9 ± 2.8 14.2 ± 1.5**
Mean arterial blood pressure, mmHg 111 ± 3 105 ± 3*
BLOOD VARIABLES   
Fasting Glucose, mmol · L-1 6.9 ± 0.6 6.6 ± 0.6*
Insulin sensitivity, (HOMA, %) 62.2 ± 8.0 77.2 ± 4.9*
β-cell function (HOMA, %) 76.8 ± 12.6 97.0 ± 9.2*
High density lipoprotein, mmol · L-1 0.69 ± 0.07 0.84 ± 0.10*
Nitric oxide, µmol· L-1 17.0 ± 6.35 22.1 ± 8.1#
Oxidized low density lipoproteins, mmol · L-1 102 ± 8 85 ± 7**
Adiponectin, µg/mL 7.8 ± 2.3 9.4 ± 3.0*
HOMA: Homeostasis Model Assessment. An estimation of steady state beta cell function and 
insulin sensitivity, as percentages of a normal reference population. 
Data are presented as mean ± SEM.  
Significant different from pre to post: * p<0.05; **  p<0.01; # p=0.07. 
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Table 2: Biological processes and molecular functions significantly altered by exercise  
 Absolute enrichment score P value 
UP-REGULATED AFTER EXERCISE   
Protein biosynthesis  1.81 0.00 
Ribosomal protein  1.92 0.00 
Krab box transcription factor 1.53 0.00 
Cytokinesis 1.67 0.01 
Zinc finger transcription factor 1.32 0.02 
Complement component 1.53 0.03 
Protein targeting and localization 1.38 0.04 
Coenzyme and prosthetic group metabolism 1.36 0.04 
Immunoglobulin receptor family member 1.38 0.04 
Steroid hormone-mediated signalling 1.55 0.05 
Anion channel 1.51 0.05 
DOWN-REGULATED AFTER EXERCISE   
Acyltransferase 1.68 0.00 
Serine protease 1.52 0.00 
Serine protease inhibitor 1.64 0.02 
CAM family adhesion molecules 1.49 0.03 
Steroid metabolism 1.44 0.03 
Amino acid catabolism 1.44 0.04 
Blood clotting 1.41 0.05 
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Table 3: Gene sets of special interest and the genes that have contributes most to their 
high enrichment score.  
Gene ID  
 STEROID HORMONE-MEDIATED SIGNALING 
2100 Estrogen receptor β  
 CAM FAMILY ADHESION MOLECULES 
1088 Carcinoembryonic antigen-related cell adhesion molecule 8 
1048 Carcinoembryonic antigen-related cell adhesion molecule 5 
257194 Neuronal growth regulator 1  
4045 Limbic system-associated membrane protein 
 AMINO ACID CATABOLISM 
144193 Amidohydrolase domain containing 1 
383 Arginase 1 
144193 Arylformamidase 
 BLOOD CLOTTING 
7450 Von Willebrand factor  
2677 Gamma-glutamyl carboxylase 
2162 Coagulation factor XIII, A1 polypeptide 
3690 Integrin 3β 
2147 Thrombin 
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